Abstracts Archive - Page 601 of 2425 - ACR Meeting Abstracts

Abstract Number: 0733 • ACR Convergence 2021
A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
Emmanuel Maheu¹, Sandrine Soriot-Thomas², Eric Noël³, Hervé Ganry⁴, Eric Lespessailles⁵ and Bernard Cortet⁶, ¹Saint-Antoine Hospital, Paris, France, ²CHU Amiens Picardie, Amiens, France, ³Santy Orthopaedic Center, Lyon, France, ⁴Hergan Consulting 4U, Amiens, France, ⁵CH Orléans, ORLEANS, France, ⁶CHU Lille, Lille, France
Background/Purpose: Knee osteoarthritis (KOA) is a frequent disease for which therapeutic possibilities are limited. In current recommendations, the first-line analgesic is acetaminophen. However, its low…
Abstract Number: 0732 • ACR Convergence 2021
Topical Rofecoxib for OA of the Knee
Bruce Register¹, Nancy Lane², Lee Simon³, John Newsam⁴, Edward Kisak⁴, Jed Pheneger⁵, John Galvin⁵, Jeffrey Klein⁶ and Marc Hochberg⁷, ¹BriOri BioTech, Inc., Newport Beach, CA, ²University of California Davis, Hillsborough, CA, ³SDG LLC, West Newton, MA, ⁴Tioga Research, Inc, San Diego, CA, ⁵Inotiv, Boulder, CO, ⁶Sinclair Research Center, Auxvasse, MO, Canada, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis remains a highly prevalent disease in the elderly, and there are currently no approved treatments that can modify the disease course. Currently, both…
Abstract Number: 0727 • ACR Convergence 2021
Total Joint Replacements in Three Phase 3 Studies of Tanezumab in Patients with Osteoarthritis
John Carrino¹, Timothy McAlindon², Eric Vignon³, Mark Brown⁴, Aimee Burr⁴, Robert Fountaine⁴, Glenn Pixton⁵, Lars Viktrup⁶, Christine West⁴ and Kenneth Verburg⁴, ¹Hospital for Special Surgery, New York, NY, ²Tufts Medical Center, Arlington, MA, ³Université Claude Bernard Lyon 1, Lyon, France, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab (TNZ) is an antibody against nerve growth factor that has demonstrated efficacy in the management of osteoarthritis (OA). Due to the potential risk…
Abstract Number: 0738 • ACR Convergence 2021
Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Weiheng Chen¹, Mengge Song¹, Yan Jia¹, Jigao Sun¹, Yan Zhao², Zhipeng Xue³, Qianglong Chen², xiangrong Zeng² and Chenchen Wang⁴, ¹The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), ²2Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), ³1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), ⁴Tufts Medical Center, Boston, MA
Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
Abstract Number: 0737 • ACR Convergence 2021
Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression
Sumir Brahmbhatt¹, Ahsan Iqbal¹, Fatemeh Farshami², Maheswari Muruganandam³, Jaren Trost⁴, David Cisneros⁵, Adnan Kiani³, N. Suzanne Emil³, Sharon Nunez¹, William Hayward⁶, Philip Band⁷ and Wilmer Sibbitt³, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, MD, ³University of New Mexico, Albuquerque, NM, ⁴Optum, Albuquerque, NM, ⁵University of New Mexico School of Medicine, Albuquerque, NM, ⁶New Mexico Highlands University, Las Vegas, NM, ⁷NYU SOM, New York, NY
Background/Purpose: To explore an alternative to standard extended knee arthrocentesis using pneumatic compression of the flexed knee.Methods: Using a paired sample design, 41 consecutive effusive…
Abstract Number: 0735 • ACR Convergence 2021
Walking Ability 12 Months After Total Knee Arthroplasty for Osteoarthritis – Gap Between Expectations and Reality: The BEST Knee Cohort Study
Lauren King, Esther Waugh and Gillian Hawker, University of Toronto, Toronto, ON, Canada
Background/Purpose: Improved ability to walk is a key driver for people with knee osteoarthritis (OA) to seek total knee arthroplasty (TKA). However, the extent to…
Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Uta Kiltz¹, Eerik Ahomaa², Björn Buehring¹, Xenofon Baraliakos¹, David Kiefer¹, Jaclyn-Dalisay Leicht¹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Vibeke Strand¹, Anthony Sebba², Savannah Scardo³, Amanda Quebe⁴, Liliana Zaremba-Pechmann⁵ and Peter C Taylor⁶, ¹Stanford University, Portola Valley, CA, ²Division of Rheumatology, University of South Florida, Tampa, FL, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indanapolis, IN, ⁵HaaPACS, Schriesheim, Germany, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…
Abstract Number: 0740 • ACR Convergence 2021
Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT
Betty Hsiao¹, Julie Downs², Mandy Lanyon², William Nowell³, SHILPA VENKATACHALAM⁴, Carole Wiedmeyer⁵, Jeffrey Curtis⁶, Susan Blalock⁷, Leslie Harrold⁸ and Liana Fraenkel⁹, ¹Yale-New Haven Medical Center, New Haven, CT, ²Carnegie Mellon, Pittsburgh, PA, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁷Chapel Hill, Chapel Hill, NC, ⁸Corrona, LLC, Northborough, MA, ⁹Berkshire Medical Center, Lenox, MA
Background/Purpose: Fewer than 50% of patients with rheumatoid arthritis (RA) are treated using a TTT strategy. The purpose of this study was to better understand…
Abstract Number: 0736 • ACR Convergence 2021
Decrease in Prevalence of Self-Reported Anxiety or Depression in Persons with Osteoarthritis After Total Knee Arthroplasty: The BEST KNEE Cohort Study
Owen Krystia, Lauren King, Esther Waugh and Gillian Hawker, University of Toronto, Toronto, ON, Canada
Background/Purpose: While anxiety and depression are highly prevalent in persons with symptomatic knee osteoarthritis (OA), few studies have assessed the effect of treatment of knee…
Abstract Number: 0730 • ACR Convergence 2021
Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study
Amy Halseth¹, Nancy Lane², Sarah Kennedy³, Christopher Swearingen¹, Victor Lopez¹, Ismail Simsek¹, Mark Fineman¹ and Yusuf Yazici⁴, ¹Biosplice Therapeutics, Inc., San Diego, CA, ²University of California Davis, Hillsborough, CA, ³Biosplice Therapeutics, Inc, San Diego, CA, ⁴New York University School of Medicine, La Jolla, CA
Background/Purpose: Knee osteoarthritis (OA) is a painful condition leading to joint damage and impaired function. Intra-articular (IA) corticosteroid injections are frequently prescribed to treat pain.…
Abstract Number: 0711 • ACR Convergence 2021
Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies
Sangmee Bae¹, Ani Shahbazian², Jennifer Wang² and Christina Charles-Schoeman², ¹University of California Los Angeles, Los Angeles, CA, ²Department of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Patients with idiopathic inflammatory myopathies have accelerated vascular disease, which contributes to higher disease morbidity and mortality. Apolipoprotein A-I (apoA-I) is the major protein…
Abstract Number: 0682 • ACR Convergence 2021
Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey
Jasvinder Singh¹ and N Lawrence Edwards², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Florida College of Medicine, Gainesville, FL
Background/Purpose: To assess gout management during the COVID-19 pandemic since September 2020.Methods: We assessed urate-lowering therapy (ULT) use, healthcare utilization, gout-specific health-related quality of life…
Abstract Number: 0619 • ACR Convergence 2021
Racial and Ethnic Disparities in Pregnancy Outcomes Among Women with Rheumatic Diseases: A Systematic Literature Review and Quantitative Analysis
Maya Swaminathan¹, Gloria Shen², Irvin Huang², Diana Louden², Waqas Tahir³ and Namrata Singh⁴, ¹MultiCare Good Samaritan Hospital, Newcastle, WA, ²University of Washington, Seattle, WA, ³Rochester General Hospital, Rochester, MN, ⁴University of Washington, Bellevue, WA
Background/Purpose: Women are disproportionately affected by rheumatic diseases (RD), with many of them carrying the diagnosis in their childbearing years. Pregnant women with RD have…
Abstract Number: 0494 • ACR Convergence 2021
The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States
Sharon Dowell¹, Huifeng Yun², Jeffrey Curtis³, Lang Chen⁴, Manuela Pedra-Nobre⁵, Dianne Wollaston⁶, SAWSAN NAJMEY⁷, Cynthia Lawrence-Elliott⁸, Theresa Lawrence-Ford⁹, Heather North¹⁰, Robin Dore¹¹, Soha Dolatabadi¹², Thaila Ramanujam¹³, Anne Winkler¹⁴, Stacy Kennedy¹⁵, Stephanie Ott¹⁶, Stephanie Ledbetter¹⁷, Grace Wright¹⁸ and Gail Kerr¹⁹, ¹Howard University College of Medicine, Washington, DC, ²University of Alabama Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama, Birmingham, AL, ⁵North Jersey Rheum. Center, Westfield, NJ, ⁶Memorial Advanced Rheumatology, Houston, TX, ⁷Midstate Rheumatology Center, PA, Freehold, NJ, ⁸North Georgia Rheum Group, Atlanta, GA, ⁹North Georgia Rheum Group, Atlanta, MD, ¹⁰Pardee UNC, Hendersonville, NC, ¹¹Robin K. Dore, MD Inc, Tustin, CA, ¹²Soha Dolatabadi, MD, Los Angeles, CA, ¹³Santa Cruz Rheumatology, Inc., Santa Cruz, CA, ¹⁴Winkler Medical Practice, Springfield, MO, ¹⁵Rowan Diagnostic Clinic, Concord, NC, ¹⁶Fairfield Medical Center, Carroll, OH, ¹⁷University of Alabama at Birmingham, Birmingham, AL, ¹⁸Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ¹⁹Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: The overall success of RA therapy is dependent on access to specialty care, insurance coverage and effective management of associated comorbidities. Whether RA disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].